The selective expression of BCMA on mature B cells and plasma cells (neoplastic cells, in particular) has made it an attractive therapeutic target for the management of plasma cells disorders, specifically multiple myeloma (MM) [4–6]. This evidence concerns the gene TNFRSF17 and AL amyloidosis.